US · PTGX
Protagonist Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Newark, CA 94560-1160
- Website
- protagonist-inc.com
Price · as of 2025-12-31
$98.37
Market cap 5.76B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $73.74 | -25.04% |
| Intrinsic Value(DCF) | $41.72 | -57.59% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $158.42 | +61.05% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $13.72 | ||||
| 2017 | $23.08 | ||||
| 2018 | $9.13 | $909.95 | $0.00 | $0.00 | $0.00 |
| 2019 | $8.11 | $30.35 | $0.00 | $0.00 | $258.61 |
| 2020 | $31.00 | $1,853.40 | $27,303.97 | $0.00 | $0.00 |
| 2021 | $25.51 | $26.66 | $4.02 | $0.00 | $0.00 |
| 2022 | $25.00 | $29.60 | $1.94 | $0.00 | $0.00 |
| 2023 | $30.32 | $49.12 | $732.53 | $0.00 | $0.00 |
| 2024 | $38.35 | $227.84 | $13,953.37 | $33.32 | $2,704.19 |
| 2025 | $94.24 | $73.74 | $6.66 | $0.00 | $158.42 |
AI valuation
Our deep-learning model estimates Protagonist Therapeutics, Inc.'s (PTGX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $73.74
- Current price
- $98.37
- AI upside
- -25.04%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$41.72
-57.59% upside
Graham-Dodd
—
— upside
Graham Formula
$158.42
+61.05% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PTGX | Protagonist Therapeutics,… | $98.37 | 5.76B | -25% | -58% | — | +61% | — | 9.75 | 130.20 | -42.43 | — | 9.75 | 97.34% | -343.63% | -282.83% | 0.00% | -97.33% | 0.00% | 0.02 | — | 12.71 | 12.49 | 0.92 | -14846.00% | -8941.00% | -6932.00% | 0.94% | 1.27 | 34.52% | 0.00% | — | 0.53% | -34.37 | 96.90 | 118.09 | 66.47 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| AKRO | Akero Therapeutics, Inc. | $54.65 | 4.5B | — | — | — | — | -11.22 | 3.77 | — | -7.43 | -37.70 | 3.77 | 0.00% | — | — | -39.22% | -1042.60% | -35.85% | 0.05 | -61.14 | 19.38 | 18.69 | 1.06 | 2976.00% | — | 5898.00% | -8.17% | -5.79 | -844.19% | 0.00% | 0.00% | 3.41% | -7.43 | -9.18 | — | 20.91 |
| ALKS | Alkermes plc | $30.10 | 4.97B | +85% | -49% | -41% | -85% | 20.62 | 2.74 | 3.38 | 13.49 | — | 2.87 | 86.31% | 17.21% | 16.37% | 14.72% | 20.15% | 10.64% | 0.04 | 20.69 | 2.06 | 1.70 | -1.57 | -3410.00% | -525.00% | -9987.00% | 0.01% | 0.00 | 0.05% | 0.00% | 0.00% | 6.08% | 17.58 | 8571.26 | 3.02 | 5.27 |
| CRNX | Crinetics Pharmaceuticals… | $41.10 | 4.21B | +36% | -54% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| IMVT | Immunovant, Inc. | $27.73 | 5.64B | — | — | — | — | -6.14 | 3.59 | — | -4.18 | -13.59 | 3.59 | 0.00% | — | — | -62.46% | 3667.16% | -57.36% | 0.00 | — | 11.16 | 10.42 | 1.63 | 4521.00% | — | 7552.00% | -14.82% | -5.47 | 3152.27% | 0.00% | 0.00% | 3.09% | -4.17 | -4.85 | — | 19.16 |
| KYMR | Kymera Therapeutics, Inc. | $91.35 | 7.31B | -43% | -53% | -100% | -68% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| NAMS | NewAmsterdam Pharma Compa… | $35.46 | 4.08B | +16% | -57% | — | +102% | — | 5.50 | 166.90 | -12.87 | — | 5.50 | 99.74% | -1002.90% | -905.74% | 0.00% | 1564.53% | 0.00% | 0.00 | — | 7.88 | 7.69 | 2.02 | -3164.00% | -5061.00% | -704.00% | -3.94% | -1.72 | 1026.20% | 0.00% | — | 0.00% | -13.82 | -21.07 | 138.63 | 24.84 |
| PTCT | PTC Therapeutics, Inc. | $68.19 | 5.47B | +340% | +35% | -42% | +1,382% | 7.73 | -25.71 | 3.05 | 4.31 | — | -7.80 | 95.85% | 49.49% | 39.44% | -104.75% | -117.79% | 29.58% | -2.40 | 5.63 | 2.35 | 2.20 | -0.55 | -26448.00% | 11451.00% | -48603.00% | 13.31% | 0.73 | -98.57% | 0.00% | 0.00% | 41.37% | 4.47 | 5.45 | 2.21 | 1.69 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
| VKTX | Viking Therapeutics, Inc. | $33.84 | 3.91B | — | — | — | — | -10.44 | 5.88 | — | -7.76 | -4.84 | 5.88 | 0.00% | — | — | -47.34% | 896.45% | -44.29% | 0.00 | -7023.96 | 9.33 | 9.21 | 0.42 | 21584.00% | — | 21745.00% | -7.42% | -3.64 | 635.14% | 0.00% | 0.00% | 3.73% | -7.76 | -10.95 | — | 27.00 |
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
- CEO
- Dinesh V. Patel
- Employees
- 124
- Beta
- 2.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($41.72 ÷ $98.37) − 1 = -57.59% (DCF, example).